share_log

Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58

Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58

Oppenheimer认为Tandem Diabetes Care表现良好,将价格目标调高至58美元
Benzinga ·  06/10 07:22

Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price target from $47 to $58.

Oppenheimer的分析师Steven Lichtman维持Tandem Diabetes Care(纳斯达克:TNDM)的跑赢市场表现评级,并将目标价从47美元上调至58美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发